SPOTLIGHT: Ranbaxy plots new buyouts

India's Ranbaxy has been on a buying spree recently, and its CEO insists that there are plenty more global acquisitions ahead. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.